Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
Pacira BioSciences (Nasdaq: PCRX) announced it will report its second quarter 2026 financial results after U.S. market close on Tuesday, August 4, 2026.
Rhea-AI Summary
Pacira BioSciences (Nasdaq: PCRX) announced it will report its second quarter 2026 financial results after U.S. market close on Tuesday, August 4, 2026. A live conference call and webcast will follow at 4:30 p.m. ET, with pre-registration required for telephone Q&A participation and a replay available on the company’s investor website for about two weeks.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PCRX
In the Jul 22 session, PCRX declined 0.74%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Reporting period
- Q2 2026
- Financial results scheduled for release
- Reporting date
- August 4, 2026
- After the close of U.S. markets
- Conference call time
- 4:30 p.m. ET
- Following the results release
- Webcast replay
- Approximately two weeks
- Replay availability following the call
Previous Earnings date Reports
-
Scheduled first-quarter results after market close with a 4:30 p.m. ET call.
-
Scheduled fourth-quarter and full-year results after market close with a webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-opioid medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter 2026 financial results after the close of the U.S. markets on Tuesday August 4, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.
Investor Contact: Pacira BioSciences, Inc. Christian Pedetti, (973) 254-4387 Christian.Pedetti@pacira.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.